FDA Approves Stelara: New Ulcerative Colitis Treatment from J&J
Stelara, recently approved by the FDA, provides a new treatment option for ulcerative colitis, promising improved outcomes for patients.
Medically Reviewed
by Dr. James Morrison, Chief Medical Officer (MD, FACP, FACC)
Reviewed on: April 08, 2026
The U.S. Food and Drug Administration (FDA) has granted FDA Stelara approval for ustekinumab (Stelara) for the treatment of moderate to severe Ulcerative Colitis in adult patients. This approval expands the indications for ustekinumab, a human monoclonal antibody developed by Johnson & Johnson, providing a new option for patients who have had an inadequate response or intolerance to conventional therapies. The ustekinumab approval is based on Phase 3 clinical trials, marking a significant advancement in treating this Inflammatory Bowel Disease.
Drug Overview
Ustekinumab (Stelara) is a human monoclonal antibody that targets the p40 subunit shared by interleukin-12 (IL-12) and interleukin-23 (IL-23). By blocking these cytokines, ustekinumab modulates inflammatory pathways implicated in ulcerative colitis pathology. It is now approved for the treatment of moderate to severe ulcerative colitis in adult patients who have had an inadequate response or intolerance to conventional therapies. Previously, ustekinumab was approved for psoriasis, psoriatic arthritis, and Crohn's disease.
Clinical Insights
The FDA approval for ustekinumab in ulcerative colitis was based on pivotal Phase 3 clinical trials. [Source: U.S. Food and Drug Administration] These trials demonstrated significant improvement in clinical remission and endoscopic response at week 8 for induction and week 44 for maintenance. Common adverse events include upper respiratory infections, headache, fatigue, and injection site reactions. Serious risks include infections due to immunosuppression and potential hypersensitivity reactions. The safety profile is consistent with other approved indications.
Regulatory Context
The FDA approval for ustekinumab followed a Biologics License Application (BLA). Typical FDA approval for biologics in ulcerative colitis involves phased clinical development: Phase 1 safety, Phase 2 dose-ranging and proof-of-concept, and Phase 3 pivotal efficacy and safety trials. The BLA submission includes clinical, nonclinical, and CMC data. Safety signals associated with ustekinumab include upper respiratory infections, headache, fatigue, and injection site reactions. Serious risks include infections due to immunosuppression and potential hypersensitivity reactions.
Market Impact
Ustekinumab enters a competitive market for ulcerative colitis treatments, including TNF inhibitors such as infliximab and adalimumab, as well as other classes like vedolizumab, risankizumab, and tofacitinib. The target population includes adult patients with moderate to severe ulcerative colitis who have had an inadequate response or intolerance to conventional therapies, representing several hundred thousand patients in the US. Ustekinumab's approval provides an additional biologic treatment option, potentially capturing patients inadequately controlled by existing therapies.
Future Outlook
Future developments for ustekinumab may include exploring label expansions and combination trials. Its unique mechanism of action targeting IL-12/23 pathways may offer advantages in specific patient subsets, warranting further investigation.
Frequently Asked Questions
What is ustekinumab (Stelara)?
Ustekinumab (Stelara) is a human monoclonal antibody that targets interleukin-12 (IL-12) and interleukin-23 (IL-23), proteins involved in inflammatory processes.
What is ustekinumab approved to treat?
Ustekinumab is approved to treat moderate to severe ulcerative colitis in adults who have not responded well to other treatments. It is also approved for psoriasis, psoriatic arthritis, and Crohn's disease.
How is ustekinumab administered?
Ustekinumab is administered via intravenous induction dosing followed by subcutaneous maintenance injections.
What are the common side effects of ustekinumab?
Common side effects include upper respiratory infections, headache, fatigue, and injection site reactions. Serious risks include infections due to immunosuppression and potential hypersensitivity reactions.
How does ustekinumab compare to other ulcerative colitis treatments?
Ustekinumab targets a unique pathway (IL-12/23) compared to existing TNF inhibitors, integrin receptor antagonists, and JAK inhibitors, offering an alternative for patients with inadequate response or intolerance to other biologics.
References
References
- U.S. Food and Drug Administration. FDA approval. Accessed 2026-04-08.
Senior Medical Editor
Dr. Sarah Chen is a board-certified internist and former FDA clinical reviewer with 15+ years of experience in pharmaceutical regulatory affairs. She received her MD from Johns Hopkins and her PhD in ...
